抗原嵌合受体T细胞(CAR-T)在非小细胞肺癌中的应用
Application of Chimeric Antigen Receptor-T Cell (CAR-T) in Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2021.1110640, PDF,    科研立项经费支持
作者: 遆嬿羽, 田智杰, 康文玥：西安医学院，陕西 西安；兀 威：西安医学院第二附属医院呼吸与危重症医学科，陕西 西安；杨淑梅：陕西省人民医院呼吸与危重症医学科，陕西 西安；李 岚：陕西省人民医院血液内科，陕西 西安
关键词: 非小细胞肺癌；CAR-T；应用；Non-Small Cell Lung Cancer； CAR-T； Application
摘要: 肺癌是世界上最常见和最致命的癌症之一，其主要有两种类型，小细胞肺癌和非小细胞肺癌，而非小细胞肺癌约占所有确诊肺癌的85%，在肺癌死亡人数中具有较大的占比，近年来，开发基因工程T细胞在基础和临床癌症研究中取得了重大进展，作为免疫治疗的新型药物，抗原嵌合受体T细胞(Chimeric antigen receptor-T cell, CAR-T)在非小细胞肺癌中显示出巨大的前景。本文就CAR-T细胞疗法在非小细胞肺癌中的应用作一综述。
Abstract: Lung cancer is one of the most common and fatal cancers in the world. There are two main types of lung cancer, small-cell carcinoma and non-small-cell lung carcinoma, and non-small-cell lung carcinoma accounts for about 85% of all diagnosed lung cancer and a large proportion of lung cancer deaths. In recent years, the development of genetically engineered T cells has made significant progress in basic and clinical cancer research as a new drug for immunotherapy. The chimeric antigen receptor-T cell (CAR-T cell) has shown great promise in non-small-cell lung carcinoma. This article reviews the application of CAR-T cell therapy in non-small-cell lung carcinoma.
文章引用：遆嬿羽, 兀威, 杨淑梅, 李岚, 田智杰, 康文玥. 抗原嵌合受体T细胞(CAR-T)在非小细胞肺癌中的应用[J]. 临床医学进展, 2021, 11(10): 4373-4377. https://doi.org/10.12677/ACM.2021.1110640

参考文献

[1] Ye, L., Lou, Y., Lu, L. and Fan, X. (2019) Mesothelin-Targeted Second Generation CAR-T Cells Inhibit Growth of Mesothelin-Expressing Tumors in Vivo. Experimental and Therapeutic Medicine, 17, 739-747. [Google Scholar] [CrossRef] [PubMed]
[2] Sullivan, R., Alatise, O.I. anderson, B.O., et al. (2015) Global Cancer Surgery: Delivering Safe, Affordable, and Timely Cancer Surgery. The Lancet Oncology, 16, 1193-224. [Google Scholar] [CrossRef] 
[3] Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30. [Google Scholar] [CrossRef] [PubMed]
[4] Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092. [Google Scholar] [CrossRef] 
[5] 罗添乐, 罗斌, 姚嘉良, 田建辉. 肺癌免疫治疗的临床研究进展[J]. 肿瘤学杂志, 2021, 27(1): 74-79.
[6] Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of the National Academy of Sciences of the United States of America, 86, 10024-10028. [Google Scholar] [CrossRef] [PubMed]
[7] 刘睿, 李亚荣. CAR-T在晚期肺癌治疗中的研究进展[J]. 中国免疫学杂志, 2018, 34(12): 1907-1911.
[8] Liu, Y. and He, Y. (2021) A Narrative Review of Chimeric Antigen Receptor-T (CAR-T) Cell Therapy for Lung Cancer. Annals of Translational Medicine, 9, 808. [Google Scholar] [CrossRef] [PubMed]
[9] Kiesgen, S., Chicaybam, L., Chintala, N.K. and Adusumilli, P.S. (2018) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology, 13, 16-26. [Google Scholar] [CrossRef] [PubMed]
[10] Greenhalgh, J., Dwan, K., Boland, A., et al. (2016) First-Line Treatment of Advanced Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Squamous Non-Small Cell Lung Cancer. Cochrane Database of Systematic Reviews, No. 5, CD010383. [Google Scholar] [CrossRef] 
[11] Qu, J., Mei, Q., Chen, L. and Zhou, J. (2021) Chimeric Antigen Receptor (CAR)-T-Cell Therapy in Non-Small-Cell Lung Cancer (NSCLC): Current Status and Future Perspectives. Cancer Immunology, Immunotherapy, 70, 619-631. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, J., Chen, J., Guo, Y., Wang, B. and Chu, H. (2017) Strategies Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer. Oncotarget, 8, 53854-53872. [Google Scholar] [CrossRef] [PubMed]
[13] Li, H., Huang, Y., Jiang, D.Q., et al. (2018) Antitumor Activity of EGFR-Specific CAR T Cells against Non-Small-Cell Lung Cancer Cells in Vitro and in Mice. Cell Death & Disease, 9, 177. [Google Scholar] [CrossRef] [PubMed]
[14] Pastan, I. and Hassan, R. (2014) Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. Cancer Research, 74, 2907-2912. [Google Scholar] [CrossRef] 
[15] Kawaguchi, T., Sho, M., Tojo, T., et al. (2010) Clinical Significance of Prostate Stem Cell Antigen Expression in Non-Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 40, 319-326. [Google Scholar] [CrossRef] [PubMed]
[16] Situ, D., Wang, J., Ma, Y., et al. (2011) Expression and Prognostic Relevance of MUC1 in Stage IB Non-Small Cell Lung Cancer. Medical Oncology, 28, S596-S604. [Google Scholar] [CrossRef] [PubMed]
[17] Wei, X., Lai, Y., Li, J., et al. (2017) PSCA and MUC1 in Non-Small-Cell Lung Cancer as Targets of Chimeric Antigen Receptor T Cells. Oncoimmunology, 6, e1284722. [Google Scholar] [CrossRef] 
[18] 覃远静, 王雪梅, 童燕娜, 等. 肿瘤血清标志物水平升高与非小细胞肺癌患者发生脑转移的关系[J]. 中华保健医学杂志, 2020, 22(2): 194-196.
[19] 翟素平, 黄秀红, 马昕炜. 血清CEA、CA125水平在靶向药物治疗非小细胞肺癌的疗效预测中的价值[J]. 实验与检验医学, 2021(39): 697-699+709.
[20] Suarez, E.R., Chang de, K., Sun, J., et al. (2016) Chimeric Antigen Receptor T Cells Secreting Anti-PD-L1 Antibodies More Effectively Regress Renal Cell Carcinoma in a Humanized Mouse Model. Oncotarget, 7, 34341-34355. [Google Scholar] [CrossRef] [PubMed]
[21] Liu, M., Wang, X., Li, W., et al. (2020) Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells. Oncogenesis, 9, 72. [Google Scholar] [CrossRef] [PubMed]
[22] Berger, C., Sommermeyer, D., Hudecek, M., et al. (2015) Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells. Cancer Immunology Research, 3, 206-216. [Google Scholar] [CrossRef] 
[23] Wallstabe, L., Göttlich, C., Nelke, L.C., et al. (2019) ROR1-CAR T Cells Are Effective against Lung and Breast Cancer in Advanced Microphysiologic 3D Tumor Models. JCI Insight, 4, e126345. [Google Scholar] [CrossRef] [PubMed]
[24] Hirsh, V. (2015) Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs, 29, 167-183. [Google Scholar] [CrossRef] [PubMed]
[25] Zhao, Y., Wang, Q.J., Yang, S., et al. (2009) A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity. The Journal of Immunology, 183, 5563-5574. [Google Scholar] [CrossRef] [PubMed]
[26] Zheng, X., Cheng, M., Fu, B., et al. (2015) Targeting LUNX Inhibits Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Research, 75, 1080-1090. [Google Scholar] [CrossRef] 
[27] Hu, Z., Zheng, X., Jiao, D., et al. (2020) LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer. Molecular Therapy—Oncolytics, 17, 361-370. [Google Scholar] [CrossRef] [PubMed]

为你推荐